Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Dec. 29, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global ...
Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...
At the recent American Society of Hematology annual meeting, phase I data highlighted a next-generation, CD19-targeted, interleukin-18-secreting "armored" CAR T-cell therapy that is designed to ...
Autolus Therapeutics plc (NASDAQ:AUTL) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, Autolus ...
Nona Biosciences, a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, ...
LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, ...
Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During their preparation for this ...
The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...
Discover why Lyell Immunopharma (LYEL) stock is up 191% YTD. Explore CAR T therapy breakthroughs, trial milestones, and key investment insights.
Zacks Investment Research on MSN
CRSP stock rises on encouraging early data from Zugo-Cel studies
Shares of CRISPR Therapeutics CRSP were up 3.7% yesterday after the company announced encouraging updates from ongoing ...
Caribou plans a pivotal Phase 3 randomized trial evaluating approximately 250 patients in second-line large B-cell lymphoma. The FDA granted vispa-cel Regenerative Medicine Advanced Therapy, Orphan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback